Indonesia Reaffirms Leadership in Global Health Diplomacy

Indonesia has played a pivotal role in ensuring equitable access to safe, high-quality, and affordable vaccines through its strategic and sustained participation in the Developing Countries Vaccine Manufacturers' Network (DCVMN). As a key driver in advancing vaccine self-reliance and public health capacity in developing countries, PT Bio Farma (Persero) has been a cornerstone of Indonesia's commitment to global health diplomacy. The 26th DCVMN Annual General Meeting, held in Bali on 29-31 October, marks a moment for Indonesia to reaffirm its leadership in this arena.

Key Takeaways:

PT Bio Farma (Persero) has been a founding member of DCVMN since its inception in 2000, collaborating on vaccine self-reliance and public health capacity in developing countries.
Bio Farma has played a vital role in expanding access to the pentavalent (DPT-HepB-Hib) vaccine through a technology-transfer collaboration with the Netherlands Vaccine Institute in 2004.
Indonesia's leadership in the global health landscape was further recognized when Bio Farma was entrusted to serve as Chair of the Board of DCVMN for the 2023-2025 period, showcasing Indonesia's capacity to lead the vaccine industry in developing countries.
Bio Farma's commitment to innovation was reflected in its nOPV2 vaccine receiving an Emergency Use Listing from the World Health Organization in 2020, marking a significant milestone in technological self-reliance and global confidence in Indonesia's capability to contribute to international health security.
As the Center of Excellence for the Organization of Islamic Cooperation (OIC) in vaccine development, production, and distribution, Bio Farma continues to strengthen Indonesia's strategic role in the global health landscape.
Bio Farma supplies vaccines to over 150 countries and holds WHO Prequalification certification for 12 types of vaccines.

Statistics:

26th DCVMN Annual General Meeting will take place in Bali on 29-31 October 2025.
DCVMN has 46 member vaccine manufacturers from 17 developing countries.
Bio Farma produces over 3.5 billion vaccine doses per year.
Bio Farma's nOPV2 vaccine received an Emergency Use Listing from the World Health Organization in 2020.
Bio Farma holds WHO Prequalification certification for 12 types of vaccines.

Sources:

DCVMN (dcvmn.org)
PT Bio Farma (Persero) (www.biofarma.co.id)
Developing Countries Vaccine Manufacturers' Network (DCVMN)
World Health Organization (WHO)
Organization of Islamic Cooperation (OIC)